Advertisement
Advertisement
ANIX
Anixa Biosciences, Inc.
3.42
USDSponsored
-0.01
-0.29%
Aug 07, 15:59 UTC -4
Closed
Pre-Market
3.37
-0.05
-1.35%
ANIX Earnings Reports
Positive Surprise Ratio
ANIX beat 22 of 31 last estimates.
71%
Next Report
Date of Next Report
Sep 08, 2026
Estimate for Q3 26 (Revenue/ EPS)
--
/-$0.08
Implied change from Q2 26 (Revenue/ EPS)
--
/+14.29%
Implied change from Q3 25 (Revenue/ EPS)
--
/+14.29%
Anixa Biosciences, Inc. earnings per share and revenue
On Jun 10, 2026, ANIX reported earnings of -0.07 USD per share (EPS) for Q2 26, beating the estimate of -0.08 USD, resulting in a 21.61% surprise. Revenue reached --, compared to an expected --, with a 0.00% difference. The market reacted with a +5.53% price change (close before vs. close after earnings).
Looking ahead to Q3 26, 5 analysts forecast an EPS of -0.08 USD, with revenue projected to reach -- USD, implying an increase of 14.29% EPS, and increase of 0.00% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
ANI Pharmaceuticals, Inc.
Report Date
Aug 07, 2026 For Q2 26
Estimate
$2.09
Actual
$2.21
Surprise
+5.69%
REGENXBIO Inc.
Report Date
Aug 06, 2026 For Q2 26
Estimate
$0.05
Actual
$0.43
Surprise
+626.35%
X4 Pharmaceuticals, Inc. Common Stock
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.18
Actual
-$0.13
Surprise
+29.19%
SAB Biotherapeutics, Inc. Common Stock
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.29
Actual
-$0.28
Surprise
+5.15%
Cellectis S.A. - ADR
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.27
Actual
-$0.22
Surprise
+20.89%
Entera Bio Ltd. Ordinary Shares
Report Date
Aug 07, 2026 For Q2 26
Estimate
-$0.08
Actual
-$0.14
Surprise
-71.57%
Genmab A/S ADS
Report Date
Aug 06, 2026 For Q2 26
Estimate
$3.59
Actual
$0.54
Surprise
-84.98%
Praxis Precision Medicines, Inc. Common Stock
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$3.73
Actual
-$2.87
Surprise
+23.14%
Halozyme Therapeutics, Inc.
Report Date
Aug 06, 2026 For Q2 26
Estimate
$1.87
Actual
$2.27
Surprise
+21.75%
Cytokinetics Inc.
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$1.67
Actual
-$1.50
Surprise
+10.35%
FAQ
What were Anixa Biosciences, Inc.'s earnings and revenue for the latest quarter Q2 2026?
For Q2 2026, Anixa Biosciences, Inc. reported EPS of -$0.07, beating estimates by 21.61%, and revenue of $0.00, 0% as expectations.
How did the market react to Anixa Biosciences, Inc.'s Q2 2026 earnings?
The stock price moved up 5.53%, changed from $2.35 before the earnings release to $2.48 the day after.
When is Anixa Biosciences, Inc. expected to report next?
The next earning report is scheduled for Sep 08, 2026.
What are the forecasts for Anixa Biosciences, Inc.'s next earnings report?
Based on 5
analysts, Anixa Biosciences, Inc. is expected to report EPS of -$0.08 and revenue of -- for Q3 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement